HIFU‐Driven Targeted Pyroptosis Therapy in Basal‐Like Breast Cancer
Advanced Science · 2025-11 · 12 (44)
DOI: 10.1002/advs.202503830 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 14.09.2025. Verfasst von Xiaomin Su und 13 weiteren Autor:innen. Beteiligte Einrichtung: Central Laboratory, First Affiliated Hospital, Institute (College) of Integrative Medicine, Dalian Medical University, Dalian, 116021, China. Hauptthemen laut MEDLINE: Pyroptosis, Breast Neoplasms, High-Intensity Focused Ultrasound Ablation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Young Medical Talents Training Program of Pudong Health Committee of Shanghai, Scientific Research Project of Shanghai Pudong Hospital.
Abstract (Originalsprache)
The high heterogeneity of basal‐like breast cancer (BLBC) and the absence of effective therapeutic targets pose ongoing treatment challenges. Pyroptosis, a type of cell death characterized by cell swelling and membrane perforation, offers a promising therapeutic weathervane for BLBC, particularly when induced by physical therapies. In this study, a high‐intensity focused ultrasound (HIFU)‐driven targeted pyroptosis strategy is developed for BLBC therapy. Through integration of HIFU‐driven gene regulation analysis and bioinformatics analysis of pyroptosis‐related genes from the TCGA dataset, 20 potential pyroptosis inducers are identified to work synergistically with HIFU. Mitoxantrone, a promising inducer, is encapsulated in platelet membrane‐hybridized liposomes to enhance targeted delivery and therapeutic efficacy. Importantly, the combination of HIFU and Plp enhanced tumor delivery of liposomes by 2.46 fold and dramatically inhibited tumor growth, with 50% of female BALB/c mice remaining tumor‐free compared to liposome‐only treatment. Mechanistically, HIFU significantly downregulated the expression of histone deacetylases 4 and 9, while promoting cathepsin‐L (CTSL) gene transcription. Simultaneously, Plp and HIFU synergistically suppressed BCL‐2 via CTSL, increasing ROS production. This activated Caspase8 and the NLRP3 inflammasome, leading to GSDMC cleavage and initiating pyroptosis. Collectively, this study provides an innovative pyroptosis therapy strategy combining physical treatment and chemotherapy for BLBC and other refractory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central Laboratory, First Affiliated Hospital, Institute (College) of Integrative Medicine, Dalian Medical University, Dalian, 116021, China.
- Pharmacy Department, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, 201399, China.
- School of Pharmacy & Key Laboratory of Smart Drug Delivery, Fudan University, Shanghai, 201203, China.
- ShuGuang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P. R. China.
- Department of Oncology, Fudan University Pudong Medical Center, Shanghai, 201399, P. R. China.
ORCID-Profile: Shun Shen
Förderung
- Young Medical Talents Training Program of Pudong Health Committee of Shanghai
- Scientific Research Project of Shanghai Pudong Hospital
Zitieren
APA
Su, X., Wang, Y., Qin, X., Xiao, Y., Ouyang, B., Hu, L., Kang, L., Xu, R., Xu, C., Sun, Z., Sun, C., Guo, H., Pang, Z., & Shen, S. (2025). HIFU‐Driven Targeted Pyroptosis Therapy in Basal‐Like Breast Cancer. Advanced Science, 12(44). https://doi.org/10.1002/advs.202503830
Vancouver
Su X, Wang Y, Qin X, Xiao Y, Ouyang B, Hu L, et al. HIFU‐Driven Targeted Pyroptosis Therapy in Basal‐Like Breast Cancer. Advanced Science. 2025;12(44). doi:10.1002/advs.202503830
BibTeX
@article{Su2025,
author = {Su, Xiaomin and Wang, Yang and Qin, Xifeng and Xiao, Yaqiong and Ouyang, Boshu and Hu, Lina and Kang, Lin and Xu, Ruizhe and Xu, Ce and Sun, Zanya and Sun, Chenyu and Guo, Huishu and Pang, Zhiqing and Shen, Shun},
title = {HIFU‐Driven Targeted Pyroptosis Therapy in Basal‐Like Breast Cancer},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {44},
doi = {10.1002/advs.202503830}
}
EUVIMED